Brief: Liminal Biosciences Provides Update On Business Strategy And Focus On Small Molecule Therapeutics

Liminal BioSciences

27/01/2021 23:02

Jan 27 (Reuters) - Liminal BioSciences Inc  LMNL.O :
    * LIMINAL BIOSCIENCES PROVIDES UPDATE ON BUSINESS STRATEGY
AND
FOCUS ON SMALL MOLECULE THERAPEUTICS
    * LIMINAL BIOSCIENCES - DETERMINED THAT PLASMA-DERIVED
THERAPEUTICS BUSINESS IS NO LONGER ALIGNED WITH NEW STRATEGY
    * LIMINAL BIOSCIENCES INC - COMMENCED PROCESS TO EVALUATE
POTENTIAL STRATEGIC ALTERNATIVES FOR PLASMA-DERIVED THERAPEUTICS
BUSINESS
    * LIMINAL BIOSCIENCES - HAS NOT MADE ANY DECISIONS RELATED
TO ANY
SPECIFIC STRATEGIC ALTERNATIVES FOR ITS PLASMA-DERIVED
THERAPEUTICS BUSINESS
    * LIMINAL BIOSCIENCES - CHANGE TO ALLOW TO FOCUS ON
DEVELOPMENT OF
LEAD PRODUCT CANDIDATE FEZAGEPRAS, SMALL MOLECULE THERAPEUTICS
DRUG DISCOVERY PROGRAM

Source text for Eikon:  ID:nCNWqlwlKa 
Further company coverage:  LMNL.O 

 ((Reuters.Briefs@thomsonreuters.com;))